Arcus Biosciences, Inc. - Common Stock (RCUS) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2018 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
RCUS on NYSE
Shares outstanding
122,470,452
Price per share
$23.83
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
89,343,889
Total reported value
$2,128,928,276
% of total 13F portfolios
0%
Share change
+13,898,966
Value change
+$345,572,310
Number of holders
139
Price from insider filings
$23.83
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Arcus Biosciences, Inc. - Common Stock (RCUS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
GILEAD SCIENCES, INC. 26% -14% $427,376,736 31,424,760 0% GILEAD SCIENCES, INC. 03 Nov 2025
BlackRock, Inc. 10% +11% $303,514,602 +$65,766,227 12,736,927 +28% BlackRock, Inc. 31 Dec 2025
Point72 Asset Management, L.P. 4.1% -28% $58,921,714 -$20,381,232 4,332,479 -26% Point72 Asset Management, L.P. 30 Sep 2025

As of 31 Dec 2025, 139 institutional investors reported holding 89,343,889 shares of Arcus Biosciences, Inc. - Common Stock (RCUS). This represents 73% of the company’s total 122,470,452 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Arcus Biosciences, Inc. - Common Stock (RCUS) together control 69% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
GILEAD SCIENCES, INC. 26% 31,424,760 0% 39% $748,852,031
BlackRock, Inc. 12% 14,997,891 +27% 0.01% $357,399,743
VANGUARD GROUP INC 6.5% 7,962,874 +20% 0% $189,755,288
STATE STREET CORP 3.7% 4,576,969 +35% 0% $109,069,171
MARSHALL WACE, LLP 2.8% 3,387,794 0.08% $80,731,131
Siren, L.L.C. 2.5% 3,007,077 +3.3% 2.1% $71,658,645
Fisher Asset Management, LLC 1.6% 1,949,788 +167% 0.02% $46,463,447
GEODE CAPITAL MANAGEMENT, LLC 1.6% 1,907,345 +19% 0% $45,459,101
BNP PARIBAS ASSET MANAGEMENT Holding S.A. 1.4% 1,687,374 +19% 0.05% $40,210,000
DIMENSIONAL FUND ADVISORS LP 1.2% 1,524,157 +1.4% 0.01% $36,316,719
MORGAN STANLEY 0.99% 1,210,754 -21% 0% $28,852,291
GOLDMAN SACHS GROUP INC 0.95% 1,168,437 +23% 0% $27,843,854
BARCLAYS PLC 0.91% 1,112,258 +528% 0.01% $26,505,110
Sofinnova Investments, Inc. 0.9% 1,096,705 -10% 1.1% $26,134,480
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.79% 968,241 +11% 0% $23,073,183
JACOBS LEVY EQUITY MANAGEMENT, INC 0.76% 929,981 -17% 0.09% $22,161,447
FRANKLIN RESOURCES INC 0.7% 853,491 0% $20,338,691
Candriam S.C.A. 0.65% 790,613 +109% 0.09% $18,841,110
Soleus Capital Management, L.P. 0.58% 711,983 0.72% $16,966,555
First Turn Management, LLC 0.46% 565,142 1.5% $13,467,334
Decheng Capital LLC 0.44% 541,559 -1.1% 1.7% $12,905,351
Bank of New York Mellon Corp 0.41% 504,462 +7.3% 0% $12,021,338
BNP PARIBAS FINANCIAL MARKETS 0.35% 424,071 0% 0.01% $10,105,612
UBS Group AG 0.34% 411,259 +146% 0% $9,800,301
PRINCIPAL FINANCIAL GROUP INC 0.33% 407,513 +22% 0% $9,711,035

Institutional Holders of Arcus Biosciences, Inc. - Common Stock (RCUS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 89,343,889 $2,128,928,276 +$345,572,310 $23.83 139
2025 Q3 100,610,243 $1,368,169,306 +$17,471,089 $13.60 186
2025 Q2 99,735,332 $811,386,525 +$23,005,595 $8.14 181
2025 Q1 97,195,653 $762,981,433 +$76,941,552 $7.85 183
2024 Q4 83,908,968 $1,249,338,646 -$21,214,675 $14.89 185
2024 Q3 53,324,923 $815,463,718 +$21,618,657 $15.29 184
2024 Q2 51,955,193 $791,285,512 -$15,709,425 $15.23 191
2024 Q1 52,828,671 $997,275,069 +$741,376 $18.88 169
2023 Q4 52,818,611 $1,008,878,346 -$1,266,933 $19.10 181
2023 Q3 52,811,112 $947,947,087 -$30,726,648 $17.95 184
2023 Q2 54,702,646 $1,110,123,478 -$11,409,103 $20.31 177
2023 Q1 55,490,875 $1,012,137,432 +$17,396,401 $18.24 177
2022 Q4 53,808,832 $1,112,728,096 +$17,661,819 $20.68 199
2022 Q3 52,505,739 $1,373,608,654 -$54,087 $26.16 171
2022 Q2 52,444,913 $1,329,092,467 -$15,970,235 $25.34 162
2022 Q1 50,609,470 $1,598,261,880 -$43,817,366 $31.56 146
2021 Q4 50,826,972 $2,056,609,533 +$107,109,155 $40.47 136
2021 Q3 48,251,727 $1,682,950,642 +$59,932,851 $34.87 127
2021 Q2 45,147,112 $1,239,729,813 +$11,589,356 $27.46 125
2021 Q1 44,736,322 $1,254,917,338 +$7,899,154 $28.08 143
2020 Q4 44,575,673 $1,157,187,273 +$10,417,742 $25.96 143
2020 Q3 44,391,126 $760,991,949 +$17,571,170 $17.14 127
2020 Q2 41,840,912 $1,034,233,021 +$380,488,277 $24.74 138
2020 Q1 26,992,583 $374,653,368 -$448,171 $13.88 92
2019 Q4 23,560,774 $237,962,351 -$3,030,738 $10.10 74
2019 Q3 25,809,690 $234,896,496 -$672,043 $9.10 73
2019 Q2 26,440,928 $210,047,107 +$6,023,856 $7.95 76
2019 Q1 25,799,127 $322,227,437 -$12,715,178 $12.49 63
2018 Q4 26,918,679 $289,911,060 -$4,742,182 $10.77 66
2018 Q3 22,437,315 $312,774,356 +$950,561 $13.94 56
2018 Q2 22,392,855 $274,091,081 +$31,576,470 $12.24 61
2018 Q1 16,255,471 $250,516,107 +$250,516,106 $15.44 55